Taguar

Main information

  • Trade name:
  • Taguar Tablet
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Taguar Tablet
    Malaysia
  • Language:
  • English

Other information

Status

  • Source:
  • NPRA - National Pharmaceutical Regulatory Agency - Bahagian Regulatori Farmasi Negara
  • Authorization number:
  • MAL09102953
  • Last update:
  • 28-05-2018

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

What is in this leaflet

1. What TAGUAR is used for

2. How TAGUAR works

3. Before you use TAGUAR

4. How to take TAGUAR

5. While you are using TAGUAR

6. Side effects

7. Storage and Disposal of TAGUAR

8. Product description

9. Manufacturer

10. Product Registration Holder

11. Date of revision

What TAGUAR is used for

TAGUAR helps to keep your blood

pressure under control. It may be used

on its own or together with other

medicines.

TAGUAR may also be used to treat

other conditions, for example, heart

failure.

How TAGUAR works

TAGUAR belongs to a group of

medicines called Angiotensin

Converting Enzyme (ACE) inhibitors.

TAGUAR relaxes your blood vessels

and this helps to lower your blood

pressure.TAGUAR also works by

helping to widen your blood vessels,

which then make it easier for your heart

to pump blood through them.

Before you use TAGUAR

When you must not take it

Pregnant, planning to become

pregnant or are breast-feeding.

Have ever had an allergic reaction

to any ingredients of TAGUAR or

to any other medicines, including

other ACE inhibitors

Have ever had a reaction which

included swelling of the hands,

lips, face or tongue where the cause

was unknown.

If any of the above affects you, or you

are unsure if they do, tell your doctor

who will be able to advise you.

Before you start to take it

Alert your doctor if you are pregnant or

if you become pregnant while being

treated with TAGUAR. Do not take

TAGUAR if you are pregnant. Do not

breastfeed while you are being treated

with TAGUAR.

You must tell your doctor if you:

suffer from kidney disease

suffer from liver disease

are undergoing dialysis

suffer from heart disease, in

particular problem with the valves

of the heart

have diabetes,

recent vomiting or excessive

diarrhea,

receive "immuno-suppressant"

therapy

If you are to have desensitisation

treatment for wasp or bee stings you

should tell the doctor who is treating

you that you are taking TAGUAR.

If you are about to have treatment for

the removal of cholesterol from your

blood by a machine, (called LDL

apheresis) you should tell your doctor

you are taking TAGUAR.

Tell your doctor you are taking

TAGUAR tablets before you have any

blood or urine tests as TAGUAR tablets

may interfere with the results of some

tests.

Taking other medicines

Inform your doctor if you are taking any

of these medicines:

other blood pressure or heart

medicines

a gout medicine called probenecid

a mood stabilizing medicine called

lithium

aspirin (higher doses)

a type of painkiller known as

NSAIDs, for example, diclofenac,

mefenamic acid, ibuprofen

diabetes medicine

potassium supplements (either as a

medicine or as a salt substitute)

Always inform your doctor and

pharmacist if you are taking any other

medicines, including herbal tonics,

supplements and medicines that you buy

without a prescription.

How to use TAGUAR

How much to use

Take TAGUAR exactly as directed by

your doctor. Do not take more or less

than instructed by your doctor.

When to use it

Take TAGUAR on an empty stomach,

at least 1 hour before or 2 hours after a

meal. Try to take it at the same time

each day.

How long to take it

TAGUAR must be taken regularly for it

to work well. Do not stop taking it

unless instructed by your doctor. Your

condition may worsen if the medicine is

stopped suddenly.

If you forget to take it

Take the missed dose as soon as you

remember. If it is almost time for your

next dose, skip the missed dose and

return to your normal schedule.

DO NOT double a dose under any

circumstances.

Remember to take your medicine

regularly. TAGUAR must be taken

exactly as directed for it to be effective.

If you often forget to take your

medicine, inform your doctor and

pharmacist

If you take too much (overdose)

If you or anyone else takes too many

tablets you should go to your nearest

hospital emergency department or tell

your doctor immediately. Take the

carton and any remaining tablets you

have with you.

While you are using it

Things you must do

Tell all doctors, dentists and pharmacists

who are treating you that you are taking

TAGUAR, especially if you are starting

on new medication.

If you become pregnant while taking

TAGUAR, tell your doctor immediately.

You should drink plenty of water while

taking TAGUAR, particularly when

exercising or in hot weather.

If you sweat a lot or are not drinking

enough water while taking TAGUAR,

you may feel light headed or faint.

This is because your blood pressure is

dropping suddenly.

If you continue to feel unwell, tell your

doctor.

If you have severe vomiting or diarrhoea

while taking TAGUAR, tell your doctor

If you plan to have desensitisation

therapy for an allergy, tell your doctor

you are taking TAGUAR.

If you are required to have any urine

tests tell your doctor you are taking

TAGUAR. TAGUAR may affect the

results of these tests.

TAGUAR TABLET 25MG

Captopril (25mg)

Consumer Medication Information Leaflet (RiMUP)

Make regular visits to your doctor so

he/she can monitor your progress.

Things you must not do

Do not lower the dose or stop taking

TAGUAR without first checking with

your doctor.

Do not use TAGUAR to treat any other

medical conditions unless your doctor

tells you to.

Do not give TAGUAR to anyone else,

even if they have the same condition as

you.

Things to be careful of

Do not lower the dose or stop taking

TAGUAR without checking first with

your doctor.

Do not use TAGUAR to treat any other

medical conditions unless your doctor

tells you to.

Do not give TAGUAR to anyone

else,even if they have the same

condition as you.

Side effects

All medicines can have side effects.

TAGUAR may cause unwanted side

effects although not everybody gets

them.

Tell your doctor or pharmacist if you

notice the following side effects:

Nausea

Vomitting

Abdominal pain

Gastric Iritation

Constipation

Anorexia

Dizziness & headache

Malaise, fatigue

Allergic reaction

Kidney disease

Liver disease

You may report any side effects or

adverse drug reactions directly to the

National Centre for Adverse Drug

Reaction Monitoring by calling Tel:03-

78835550, or visiting the website

portal.bpfk.gov.my (Consumers →

Reporting)

Storage and Disposal of TAGUAR

Storage

Storage below 30°C. Protect from

moisture.

Disposal

Tell your doctor if you stop taking

TAGUAR or the expiry date has

passed, ask your pharmacist what to do

with any leftover tablets.

Product Description

What it looks like

White, round,flat tablets, scored on one

side and plain on the other side with

diameter about 8mm.

Ingredients

Active Ingredient

Each tablet contains 25mg Captopril.

Non-active Ingredient

In addition,TAGUAR contains lactose

monohydrate, maize starch,

microcrystalline cellulose and stearic

acid.

MAL Number

MAL09102953A

Manufacturer

AUROBINDO PHARMA LIMITED

Unit III, Survey No. 313,Bachupally

Village, Quthubullapur Mandal, Ranga

Reddy District, (A.P),India

Product Registration Holder

PRESTIGE PHARMA SDN BHD

No.22A, Jalan Wangsa Delima 2A,

Pusat Bandar Wangsa Maju

53300 Kuala Lumpur

Date of Revision

30/01/2014

TAGUAR TABLET 25MG

Captopril (25mg)

Consumer Medication Information Leaflet (RiMUP)

30-11-2018

Data collection for the estimation of ecological data (specific focal species, time spent in treated areas collecting food, composition of diet), residue level and residue decline on food items to be used in the risk assessment for birds and mammals

Data collection for the estimation of ecological data (specific focal species, time spent in treated areas collecting food, composition of diet), residue level and residue decline on food items to be used in the risk assessment for birds and mammals

Published on: Thu, 29 Nov 2018 The study described in this report was conducted with the aim of developing an unified database of ecological data and residue data to be used for the risk assessment of plant protection products for birds and mammals. The main sources of data were the information submitted in the context of approval of active substances and authorization of products and and additional information retrieved through a systematic literature review. The data were screened and organised in thr...

Europe - EFSA - European Food Safety Authority Publications

24-7-2018

Opinion/decision on a Paediatric investigation plan (PIP):    Penthrox, Methoxyflurane, Therapeutic area: Pain

Opinion/decision on a Paediatric investigation plan (PIP): Penthrox, Methoxyflurane, Therapeutic area: Pain

Europe - EFSA - European Food Safety Authority EFSA Journal

22-11-2018

EU/3/17/1933 (Emerald Health Pharmaceuticals EspaNa, S.L.)

EU/3/17/1933 (Emerald Health Pharmaceuticals EspaNa, S.L.)

EU/3/17/1933 (Active substance: (1'R,6'R)-3-(benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione) - Transfer of orphan designation - Commission Decision (2018)7813 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000001966

Europe -DG Health and Food Safety

1-10-2018

EU/3/05/328 (Celgene Europe B.V.)

EU/3/05/328 (Celgene Europe B.V.)

EU/3/05/328 (Active substance: (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone) - Transfer of orphan designation - Commission Decision (2018)6434 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/056/05/T/03

Europe -DG Health and Food Safety

1-10-2018

EU/3/05/279 (Celgene Europe B.V.)

EU/3/05/279 (Celgene Europe B.V.)

EU/3/05/279 (Active substance: (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone) - Transfer of orphan designation - Commission Decision (2018)6433 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/001/05/T/03

Europe -DG Health and Food Safety

24-9-2018

Diacomit (Biocodex)

Diacomit (Biocodex)

Diacomit (Active substance: Stiripentol) - Centralised - Renewal - Commission Decision (2018)6254 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/664/R/21

Europe -DG Health and Food Safety

15-5-2018

Fevaxyn Pentofel (Zoetis Belgium S.A.)

Fevaxyn Pentofel (Zoetis Belgium S.A.)

Fevaxyn Pentofel (Active substance: Not available) - Centralised - Yearly update - Commission Decision (2018)2990 of Tue, 15 May 2018

Europe -DG Health and Food Safety